


## Data Sheet

<b>Product Name:</b>	LY2886721
<b>Cat. No.:</b>	CS-0458
<b>CAS No.:</b>	1262036-50-9
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>16</sub> F <sub>2</sub> N <sub>4</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	390.41
<b>Target:</b>	Beta-secretase
<b>Pathway:</b>	Neuronal Signaling
<b>Solubility:</b>	DMSO : ≥ 16.67 mg/mL



### BIOLOGICAL ACTIVITY:

LY2886721 is a potent, selective and orally active **beta-site amyloid precursor protein cleaving enzyme 1 (BACE1)** inhibitor with an **IC<sub>50</sub>** of 20.3 nM for recombinant human **BACE1**. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against **BACE2** (**IC<sub>50</sub>** of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment<sup>[1]</sup>. **IC<sub>50</sub> & Target:** IC<sub>50</sub>: 20.3 nM (Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1)); 10.2 nM (BACE2)<sup>[1]</sup> *In Vitro:* Overnight exposure of HEK293Swe cells to increasing concentrations of LY2886721 shows a concentration-dependent decrease in the amount of Aβ secreted into the condition medium. Consistent with a mechanism of BACE inhibition, the EC<sub>50</sub>s for inhibition of Aβ<sub>1-40</sub> and Aβ<sub>1-42</sub> are essentially identical, 18.5 and 19.7 nM, respectively<sup>[1]</sup>. Overnight exposure of PDAPP neuronal cultures to an increasing concentration of LY2886721 produces a concentration-dependent decrease in Aβ production. As observed in HEK293Swe cells, the EC<sub>50</sub>s for inhibition of Aβ<sub>1-40</sub> and Aβ<sub>1-42</sub> are comparable in PDAPP neuronal cultures at □10 nM<sup>[1]</sup>. *In Vivo:* LY2886721 (3-30 mg/kg; oral administration; PDAPP mice) treatment significantly reduces the hippocampal and cortical levels of Aβ<sub>1-x</sub>. LY2886721 treatment results in significant reduction of brain parenchymal levels of C99 and sAPPβ<sup>[1]</sup>.

### References:

[1]. May PC1, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35(3):1199-210.

### CAIndexNames:

2-Pyridinecarboxamide, N-[3-[(4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-

### SMILES:

FC1=CN=C(C=C1)C(NC2=CC=C(C([C@@]34[C@]([H])(CSC(N)=N4)COC3)=C2)F)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA